Condition: TP53 Gene Mutation · Multi-Gene Transcriptional Profiling · TP53 Gene Germline Mutation Carrier · Sponsor: European Institute of Oncology
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.
This description comes directly from the study's public registry record.
Mariarosaria Calvello, MD · +39 0294372651 · mariarosaria.calvello@ieo.it
Always discuss trial participation with your own doctor first.
| Istituto Europeo di Oncologia | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07419893